Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Down 17.1% in December

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the target of a large decline in short interest in the month of December. As of December 31st, there was short interest totaling 220,322 shares, a decline of 17.1% from the December 15th total of 265,860 shares. Based on an average daily trading volume, of 157,036 shares, the short-interest ratio is currently 1.4 days. Currently, 1.4% of the shares of the company are sold short. Currently, 1.4% of the shares of the company are sold short. Based on an average daily trading volume, of 157,036 shares, the short-interest ratio is currently 1.4 days.

Institutional Trading of Allarity Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ALLR. Capital Advisors Inc. OK acquired a new stake in shares of Allarity Therapeutics during the 4th quarter valued at $108,000. Citadel Advisors LLC purchased a new position in Allarity Therapeutics during the 3rd quarter valued at about $149,000. Private Advisor Group LLC acquired a new position in Allarity Therapeutics in the 3rd quarter valued at approximately $441,000. Jane Street Group LLC acquired a new position in shares of Allarity Therapeutics in the second quarter worth $27,000. Finally, XTX Topco Ltd purchased a new position in Allarity Therapeutics in the second quarter valued at about $51,000. 11.53% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have issued reports on ALLR shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Allarity Therapeutics in a report on Wednesday, October 8th. Ascendiant Capital Markets boosted their price objective on Allarity Therapeutics from $9.25 to $9.50 and gave the company a “buy” rating in a research report on Tuesday, December 9th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $9.50.

Allarity Therapeutics Stock Performance

Shares of ALLR stock opened at $1.16 on Wednesday. The firm has a market capitalization of $18.33 million, a PE ratio of -1.97 and a beta of 0.23. Allarity Therapeutics has a 1 year low of $0.61 and a 1 year high of $2.35. The stock has a fifty day moving average of $1.13 and a two-hundred day moving average of $1.26.

Allarity Therapeutics (NASDAQ:ALLR) last announced its earnings results on Friday, November 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.04. Equities research analysts predict that Allarity Therapeutics will post -78.08 earnings per share for the current fiscal year.

Allarity Therapeutics Company Profile

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.